Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...